Clinical Trial Update: UMD rPA Regimen Trial in Adults [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the UMD rPA regimen in adults with anthrax has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• rPA (recombinant protective antigen (rPA))

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Bacillus Anthracis (Anthrax) | Phase 2 | Status: TERMINATED